Research
Hormonal
In patients with type 2 diabetes and established cardiovascular disease, GLP-1 receptor agonists or SGLT2 inhibitors with demonstrated cardiovascular benefit are recommended when glycemic goals are not achieved with metformin.
Practitioners should consider GLP-1 receptor agonists or SGLT2 inhibitors for patients with type 2 diabetes who have cardiovascular disease and are not meeting glycemic targets with metformin.
StrongSupportsmedium confidence
agents from the GLP-1 receptor agonist or SGLT2 inhibitor classes with demonstrated cardiovascular benefit constitute the recommended treatment.
Why this rating
The claim is based on established treatment guidelines for a specific patient population.
Source
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Rita R. Kalyani · New England Journal of Medicine · 2021
DOI 10.1056/nejmcp2000280
otherCited 92×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →